Fortitude Family Office’s Pacific Biosciences PACB Stock Holding History

Fortitude Family Office’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,131	Closed	-$1.9K	–	2718
2026 Q2	$1.9K	Buy	+1,131	New	+$1.64K	﹤0.01%	1499
2026 Q1	–	Sell	-793	Closed	-$1.48K	–	2024
2025 Q4	$1.48K	Hold	793	–	–	﹤0.01%	1297
2025 Q3	$1.01K	Buy	+793	New	+$1.07K	﹤0.01%	1544
2025 Q2	–	Sell	-1,950	Closed	-$2.3K	–	2102
2025 Q1	$2.3K	Hold	1,950	–	–	﹤0.01%	902
2024 Q4	$3.57K	Hold	1,950	–	–	﹤0.01%	922
2024 Q3	$3.31K	Buy	+1,950	New	+$3.2K	﹤0.01%	905

Other funds holding PACB

MCP

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

KWM

Koa Wealth Management Encinitas, California $154M AUM 13.16% 1-Year Est. Return

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

VVP

Venture Visionary Partners Sylvania, Ohio $3.82B AUM 21.33% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

DWM

DKM Wealth Management Stockton, California $158M AUM 11.62% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fortitude Family Office's PACB Position: Q3 2026 in Review

Fortitude Family Office sold out of Pacific Biosciences (PACB) in Q3 2026, closing a stake of 1,131 shares — an estimated $1.9K sold.

Fortitude Family Office first reported a position in PACB in Q3 2024 and held it in 6 quarters. The position peaked at $3.57K in Q4 2024. 8 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

Fortitude Family Office reported no remaining Pacific Biosciences position as of Q3 2026 after selling out during the quarter.
Fortitude Family Office sold 1,131 Pacific Biosciences shares in Q3 2026, an estimated $1.9K.
Fortitude Family Office first reported a position in Pacific Biosciences in Q3 2024 and held it in 6 quarters.
Fortitude Family Office's Pacific Biosciences position peaked at $3.57K in Q4 2024.
8 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.